The impact of the COVID-19 pandemic on renal cancer care

• by Hilin Yildirim, Adriaan D. Bins, Corina van den Hurk, R. Jeroen A. van Moorselaar, Martijn G. H. van Oijen, Axel Bex, Patricia J. Zondervan, Katja K. H. Aben

• April 13, 2024

Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges

• by Shuyu Ren, Fangfang Pan, Jie Jin

• May 14, 2026

Comprehensive analysis of fatty acid desaturase 3 in clear cell renal cell carcinoma: insights into tumor progression, immune microenvironment, and clinical outcomes

• by Si-Tao Chen, Duan-Rui Zhou, Yun-Jun Ge, Lei Chang, Shu-Hui Guo, Guo-Sheng Wu, Ning-Han Feng

• May 14, 2026

Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

• by

• May 19, 2026

• 7 min